The U.S. Food and Drug Administration approved a third over-the-counter naloxone nasal spray on June 16, 2026, broadening public access to the opioid overdose reversal medication. The new product, called Rextovy — a 4-milligram naloxone hydrochloride nasal spray manufactured by Amphastar Pharmaceuticals — is now available for direct purchase without a prescription at pharmacies, convenience stores, and online.
Naloxone reverses opioid overdose by blocking opioid receptors in the brain. When administered to someone who has stopped breathing or lost consciousness due to opioid overdose — including fentanyl overdose — it can restore normal breathing within two to three minutes. A person who has overdosed cannot administer it to themselves. Only a bystander, family member, or first responder can deliver the medication in time.
